Flexion Therapeutics Stock Forecast, Price & News

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

Is Flexion Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last twelve months. There are currently 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Flexion Therapeutics stock.
View analyst ratings for Flexion Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Flexion Therapeutics?

Wall Street analysts have given Flexion Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Flexion Therapeutics.

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings data on Wednesday, August, 4th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.50) by $0.06. The specialty pharmaceutical company earned $28.18 million during the quarter, compared to the consensus estimate of $28.02 million.
View Flexion Therapeutics' earnings history.

How has Flexion Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FLXN stock has decreased by 46.8% and is now trading at $6.55.
View which stocks have been most impacted by COVID-19.

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $120 million-$130 million, compared to the consensus revenue estimate of $133.34 million.

What price target have analysts set for FLXN?

8 analysts have issued 1-year price objectives for Flexion Therapeutics' shares. Their forecasts range from $6.00 to $22.00. On average, they expect Flexion Therapeutics' share price to reach $15.17 in the next year. This suggests a possible upside of 131.6% from the stock's current price.
View analysts' price targets for Flexion Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:

• Michael D. Clayman, President, Chief Executive Officer & Director
• Fred Driscoll, Chief Financial Officer
• William T. Andrews, Chief Medical Officer
• Carolyn Beaty Scimemi, Chief Compliance Officer & Head-Legal Affairs
• Christina Willwerth, Chief Strategy Officer (LinkedIn Profile)

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among Flexion Therapeutics' employees.

Who are some of Flexion Therapeutics' key competitors?

Some companies that are related to Flexion Therapeutics include COMPASS Pathways (CMPS), Connect Biopharma (CNTB), Arcturus Therapeutics (ARCT), Avid Bioservices (CDMO), Y-mAbs Therapeutics (YMAB), Axsome Therapeutics (AXSM), MacroGenics (MGNX), Heron Therapeutics (HRTX), Kronos Bio (KRON), Innoviva (INVA), Northwest Biotherapeutics (NWBO), Olema Pharmaceuticals (OLMA), MannKind (MNKD), ImmunoGen (IMGN) and Enanta Pharmaceuticals (ENTA).
View all of FLXN's competitors.

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.54%), Wasatch Advisors Inc. (8.32%), State Street Corp (7.91%), Artisan Partners Limited Partnership (6.47%), Vanguard Group Inc. (5.18%) and Goldman Sachs Group Inc. (2.22%). Company insiders that own Flexion Therapeutics stock include Adam Muzikant, Christina Willwerth, David Arkowitz, Mark S Levine, Mark Stejbach, Melissa Layman and Michael D Clayman.
View institutional ownership trends for Flexion Therapeutics.

Which major investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Deutsche Bank AG, Versant Venture Management LLC, BlackRock Inc., Nuveen Asset Management LLC, Kingdon Capital Management L.L.C., SG Americas Securities LLC, and Wasatch Advisors Inc.. Company insiders that have sold Flexion Therapeutics company stock in the last year include Adam Muzikant, Christina Willwerth, David Arkowitz, Mark S Levine, and Melissa Layman.
View insider buying and selling activity for Flexion Therapeutics or view top insider-selling stocks.

Which major investors are buying Flexion Therapeutics stock?

FLXN stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Millennium Management LLC, Blair William & Co. IL, PDT Partners LLC, M&G Investment Management Ltd., Artisan Partners Limited Partnership, and Citigroup Inc.. Company insiders that have bought Flexion Therapeutics stock in the last two years include Mark Stejbach, and Michael D Clayman.
View insider buying and selling activity for Flexion Therapeutics or or view top insider-buying stocks.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $6.55.

How much money does Flexion Therapeutics make?

Flexion Therapeutics has a market capitalization of $329.41 million and generates $85.55 million in revenue each year. The specialty pharmaceutical company earns $-113,710,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Flexion Therapeutics have?

Flexion Therapeutics employs 257 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

Where are Flexion Therapeutics' headquarters?

Flexion Therapeutics is headquartered at 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at (781) 305-7777 or via email at [email protected].